Stay updated on Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page.

Latest updates to the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed detailed information about a clinical study on risankizumab for psoriasis, including its purpose, inclusion and exclusion criteria, and the study's title, while adding a new revision number.SummaryDifference9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page.